[ad_1] Ventyx Biosciences VTYX announced positive data from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a novel and selective allosteric TYK2 inhibitor.…
[ad_1] The European Commission (EC) has granted marketing authorization for Argenx’s ARGX lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with…
[ad_1] Rain Therapeutics RAIN has completed patient enrolment in its Phase 3 MANTRA trial of its lead asset, milademetan for well-differentiated / dedifferentiated (WD/DD) liposarcoma (LPS). The MANTRA study is…
[ad_1] The U.S. Food and Drug Administration (FDA) accepted for review ImmunityBio’s IBRX Biologics License Application (BLA) for its lead asset N-803 in the treatment of patients with BCG-unresponsive non-muscle-invasive…
[ad_1] Turning Point Therapeutics TPTX has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter. The pre-NDA…